Delayed Treatment With Nicotinamide (Vitamin B 3 ) Improves Neurological Outcome and Reduces Infarct Volume After Transient Focal Cerebral Ischemia in Wistar Rats
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background and Purpose —We have previously shown that nicotinamide (NAm) acutely reduces brain infarction induced by permanent middle cerebral artery occlusion (MCAo) in rats. In this study, we investigate whether NAm may protect against ischemia/reperfusion injury by improving sensory and motor behavior as well as brain infarction volumes in a model of transient focal cerebral ischemia. Methods —Forty-eight male Wistar rats were used, and transient focal cerebral ischemia was induced by MCAo for 2 hours, followed by reperfusion for either 3 or 7 days. Animals were treated with either intraperitoneal saline or NAm (500 mg/kg) 2 hours after the onset of MCAo (ie, on reperfusion). Sensory and motor behavior scores and body weight were obtained daily, and brain infarction volumes were measured on euthanasia. Results —Relative to treatment with saline, treatment with NAm (500 mg/kg IP) 2 hours after the onset of transient focal cerebral ischemia in Wistar rats significantly improved sensory (38%, P <0.005) and motor (42%, P <0.05) neurological behavior and weight gain (7%, P <0.05) up to 7 days after MCAo. The cerebral infarct volumes were also reduced 46% ( P <0.05) at 3 days and 35% ( P =0.09) at 7 days after MCAo. Conclusions —NAm is a robust neuroprotective agent against ischemia/reperfusion-induced brain injury in rats, even when administered up to 2 hours after the onset of stroke. Delayed NAm treatment improved both anatomic and functional indices of brain damage. Further studies are needed to clarify whether multiple doses of NAm will improve the extent and duration of this neuroprotective effect and to determine the mechanism(s) of action underlying the neuroprotection observed. Because NAm is already used clinically in large doses and has few side effects, these results are encouraging for the further examination of the possible use of NAm as a therapeutic neuroprotective agent in the clinical treatment of acute ischemic stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bederson, J. B., Pitts, L. H., Tsuji, M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. (1986) · Stroke · doi:10.1161/01.str.17.3.472 · Cited by 2,681
Nitric Oxide Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity
Zhang, J., Dawson, V. L., Dawson, T. M., & Snyder, S. H. (1994) · Science · doi:10.1126/science.8080500 · Cited by 1,118
Experimental studies of ischemic brain edema
Koizumi, J.-I., Yoshida, Y., Nakazawa, T., & Ooneda, G. (1986) · Nosotchu · doi:10.3995/jstroke.8.1 · Cited by 996
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Cited by
Ying, W. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1672 · Cited by 1,494
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias
Macleod, M. R., O’Collins, T., Howells, D. W., & Donnan, G. A. (2004) · Stroke · doi:10.1161/01.str.0000125719.25853.20 · Cited by 730
Therapeutic applications of compounds in the Magnolia family
Lee, Y.-J., Lee, Y. M., Lee, C.-K., Jung, J. K., Han, S. B., & Hong, J. T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.010 · Cited by 481
Zhang, Y., Yang, X., Ge, X., & Zhang, F. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.161 · Cited by 309
Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications
Gasperi, V., Sibilano, M., Savini, I., & Catani, M. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040974 · Cited by 277
Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment
Hwang, E., & Song, S. (2020) · Biomolecules · doi:10.3390/biom10050687 · Cited by 144
Nicotinamide extends replicative lifespan of human cells
Kang, H. T., Lee, H. I., & Hwang, E. S. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00234.x · Cited by 105
“…damage (Guruprasad et al. , 2002), protects brain cells from oxidative damage caused by reperfusion after ischemic infarction (Sun & Cheng, 1998; Mokudai et al. , 2000; Klaidman et al. , 2003), and prevents injury of pancreatic islet cells during free radical exposure (Kallmann et al. , 1992).”
BackgroundGlaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Williams, P. A., Harder, J. M., & John, S. W. M. (2017) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000767 · Cited by 102
Aidar, F. J., de Oliveira, R. J., Silva, A. J., de Matos, D. G., Carneiro, A. L., Garrido, N., Hickner, R. C., & Reis, V. M. (2011) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-9-89 · Cited by 36
Metadata
- Authors
- Mokudai, T., Ayoub, I. A., Sakakibara, Y., Lee, E.-J., Ogilvy, C. S., & Maynard, K. I.
- Venue
- Stroke
- Published
- 2000-07
- Volume
- 31
- Issue
- 7
- Pages
- 1679-1685
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W1950821376
- Cited by
- 129
- References
- 4
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.